Despite promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from pharmacy benefit managers. The insurers are https://henridolw995311.blogtov.com/22721046/the-vyndamax-faces-is-dealing-with-pharmacy-benefit-manager-hurdles-a-look-at-coverage-disputes